We are a purpose-driven, commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. We involve key thought leaders, physicians, patients, care partners, and advocacy groups in all of our clinical and regulatory development strategies. With a keen understanding that drug development often requires creative solutions, we have the insight and expertise to forge new pathways to success that others have missed. By following the data without bias, our transparent narratives and common-sense perspective have successfully overcome complex development challenges to make much-needed therapies available to patients. Nimble and dauntless, we push boundaries beyond what is thought to be possible and advance new therapies that have the potential to bring meaningful improvement to patients’ lives.
| Website | http://www.zevra.com |
| Revenue | $24.5 million |
| Employees | 79 (51 on RocketReach) |
| Founded | 2006 |
| Address | 101 Federal St 29th Floor, Boston, Massachusetts 02110, US |
| Industry | Biotechnology Research |
| Keywords | Rare Disease Therapeutics, Drug Development, Pharmaceutical Research, Clinical Trials, Biotechnology, Patient Advocacy, Unmet Medical Needs, Drug Discovery, Pharmaceutical, Therapeutics, Biopharma, Medical Research, Clinical Development, Drug Pipeline, Regulatory Affairs, Healthcare |
| Competitors | Amgen, Vertex Pharmaceuticals, Apellis Pharmaceuticals, Acorda Therapeutics, Inc., Liquidia Corporation, PsychoGenics, Catalyst Pharmaceuticals, Inc., Akcea Therapeutics, Prader-Willi Syndrome Association | USA, Amicus Therapeutics +31 more (view full list) |
Looking for a particular Zevra Therapeutics employee's phone or email?
The Zevra Therapeutics annual revenue was $24.5 million in 2026.
Neil McFarlane is the CEO of Zevra Therapeutics.
51 people are employed at Zevra Therapeutics.
Zevra Therapeutics is based in Boston, Massachusetts.